Atopic march biologic selection
Biologic and JAK inhibitor selection across the atopic march (atopic dermatitis, allergic asthma, CRSwNP, EoE), anchored by shared type-2 targets and coexisting disease.
Evidence tier: Expert consensus. Reflects expert-consensus criteria, not a prospectively validated instrument. Apply clinical judgment and local policy.
| Agent (target) | Primary indication(s) | Atopic march coverage, coexisting benefits |
|---|---|---|
| Dupilumab (anti–IL-4Rα) | Moderate-severe atopic dermatitis (AD) age ≥6 months; moderate-severe asthma (eos ≥150 or FeNO ≥25); CRSwNP; EoE (age ≥12); prurigo nodularis; COPD (eos ≥300) | Single agent that covers every major atopic march comorbidity. The dominant choice when a patient has AD + asthma + nasal polyps or AD + EoE. IL-4Rα blockade reduces IgE, Th2 cytokines, and epithelial barrier defects simultaneously. |
| Tralokinumab (anti–IL-13) | Moderate-severe AD (age ≥18) | Selective IL-13 blockade; narrower atopic march coverage than dupilumab (no approved asthma or CRSwNP indication). Preferred when AD is isolated or when dupilumab is not tolerated. |
| Lebrikizumab (anti–IL-13) | Moderate-severe AD (age ≥12) | Same mechanism as tralokinumab; different epitope on IL-13. Minimal atopic march cross-coverage outside AD. Choose dupilumab when comorbid asthma or nasal polyps are also present. |
| Omalizumab (anti-IgE) | Allergic asthma (US asthma dosing table: total IgE 30-700 IU/mL if >=12 y, 30-1300 if 6-11 y; perennial aeroallergen sensitized); CSU (fixed dosing, not IgE-based); CRSwNP | Covers allergic asthma and urticaria comorbidities in the atopic march. Does not improve AD significantly in trials. Consider when allergic asthma is the dominant driver and serum IgE is in range. |
| Mepolizumab / benralizumab / reslizumab (anti–IL-5/IL-5Rα) | Severe eosinophilic asthma; EGPA (mepolizumab); CRSwNP (mepolizumab); HES (mepolizumab) | Cover eosinophilic phenotype of asthma and associated CRSwNP. Not effective for AD. Consider when blood eosinophilia is the dominant march driver alongside severe asthma. |
| Tezepelumab (anti-TSLP) | Severe asthma regardless of eosinophil count; no biomarker threshold required | Upstream alarmin blockade reduces type-2 AND non-type-2 asthma; may also reduce allergic sensitization (trials ongoing). No AD or EoE approval. The asthma agent of choice when eosinophils are low but AD is not the primary concern. |
| Abrocitinib / upadacitinib (JAK1 inhibitors, oral) | Moderate-severe AD (age ≥12) | Fastest onset among AD biologics/JAKi. No asthma or CRSwNP indication. Risk: thrombosis, serious infection, malignancy (boxed warning). Reserve for patients with inadequate response to dupilumab or IL-13 inhibitors when AD is the primary driver. |
Notes
- Dupilumab is the preferred agent for patients with overlapping atopic dermatitis + asthma + CRSwNP or EoE, it is the only biologic approved across all four conditions.
- Measure FeNO, blood eosinophils, and total IgE before starting any biologic, these guide asthma phenotyping and distinguish type-2 from non-type-2 disease.
- JAK inhibitors (abrocitinib, upadacitinib) carry a boxed warning for MACE, malignancy, thrombosis, and serious infection, use after biologics fail, with full informed consent.
- The atopic march is not a linear progression in every patient, treat each active condition and re-evaluate rather than waiting for the "next step" of the march to emerge.
- Dupilumab-associated conjunctivitis (20-30%) and facial erythema are class effects; switch to tralokinumab or lebrikizumab if these are intolerable and asthma/CRSwNP are not active comorbidities.
Evidence & citations
- Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588. PMID 31558662
- Silverberg JI, Thyssen JP, Fahrbach K, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol. 2021;35(9):1797-1810. PMID 33991374
- Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650. PMID 31543428
- Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022;387(25):2317-2330. PMID 36546624
Clinician decision support. Verify against the cited source. Not a substitute for clinical judgment. 100% on-device; no patient data is stored or transmitted.